4

4D Molecular Therapeutics

Develops gene therapies using AAV vectors

Executive Medical Director - Retina Program

Biology & BiotechUpdated on Nov 3
Full-timeRemote in USA$350k - $398k

About the Job

Requirements

  • An M.D. is required, although other degrees may be considered with relevant experience.
  • Residency training in Ophthalmology is required; subspecialty training in retina is preferred.
  • At least 10 years of clinical ophthalmology research experience in the biopharmaceutical industry is required.
  • Experience with medical monitoring and oversight of Phase 1 retina clinical trials is required.
  • Experience with gene therapy clinical studies is required.
  • Knowledge of ICH-GCP and FDA regulatory guidelines is required.
  • Knowledge of international regulatory guidelines is required.
  • Effective written and verbal communication skills, including public speaking, are required.

Responsibilities

  • Design, execute, and analyze clinical trials in the ophthalmology therapeutic area.
  • Serve as clinical lead for Phase 1 retina clinical trials, including study design, protocol development, dose escalation strategy, and safety oversight.
  • Maintain accountability for study execution, data interpretation, and clinical readouts, including early signal detection and go/no-go recommendations.
  • Serve as medical monitor for assigned studies, ensuring subject safety and data integrity.
  • Lead cross-functional study teams to ensure high-quality and timely trial delivery.
  • Provide clinical leadership to multidisciplinary study execution teams drawn from clinical operations, clinical science, biometrics, regulatory affairs, CMC, pharmacology and toxicology, drug safety, commercial, and alliance partners.
  • Hold lead accountability on study teams for delivery of study protocols, study conduct, and study readouts.
  • Lead development and implementation of biomarker strategies for GA and broader retina programs.
  • Collaborate with research and translational teams to identify, validate, and integrate imaging, molecular, and functional biomarkers into early-phase trials.
  • Ensure biomarkers are aligned with mechanism of action, dose selection, and clinical endpoints to support decision-making and regulatory strategy.
  • Serve as the primary clinical author of development plans, protocols, investigator brochures, INDs, clinical study reports, and regulatory responses.
  • Lead clinical contributions to IND submissions and early regulatory interactions, including Health Authority meetings for Phase 1 programs.
  • Ensure accuracy, scientific rigor, and regulatory compliance of clinical documents.
  • Organize and lead scientific advisory board meetings and interact with external experts and stakeholders to gather input.
  • Work with the research organization and portfolio management team to identify and support new project opportunities.
  • Collaborate to identify program risks and create and implement mitigation strategies.
  • Perform other duties as assigned.

Desired Qualifications

  • Retina subspecialty training is preferred.
  • Board certification and retina fellowship training are a plus.
  • Experience in Phase 2 and Phase 3 clinical research is desirable.
  • Experience with NDA, BLA, and MAA submission planning and execution is desirable.
  • Experience in data analysis, data interpretation, and medical writing is desirable.

About the Company

4D Molecular Therapeutics

Develops gene therapies using AAV vectors

4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.

Company size
201-500
Company stage
IPO
Headquarters
Emeryville, CA
Founded
2013

Recently Posted Jobs

Explore more opportunities at 4D Molecular Therapeutics

See more jobs